STOCK TITAN
  1. Home
  2. News
  3. LUCD

Lucid Diagnostics Inc - LUCD STOCK NEWS

Welcome to our dedicated news page for Lucid Diagnostics (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lucid Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lucid Diagnostics's position in the market.

News
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) announced that their President & COO will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The webcast will be available on their website, with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
News
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
PAVmed Inc. reports a 33% sequential increase in quarterly revenue and launches PMX incubator for technology development. Lucid Diagnostics Inc. shows revenue growth and expansion in clinical data evidence. Veris Health Inc. focuses on financing from academic and regional cancer centers. Financially, the company had a net loss but positive revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) reports a 33% sequential increase in Quarterly EsoGuard® revenue. The company is focused on expanding clinical validity and utility data to drive medical policy coverage, including potential Medicare coverage. Lucid's recent business update highlights revenue growth, stable test volume, improving revenue cycle management, and progress in engaging with major commercial payors for positive coverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
earnings
News
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Rhea-AI Summary
Lucid Diagnostics Inc. announces promising results from a VA screening study showing EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% for esophageal precancer detection. The study highlights EsoGuard as a powerful screening tool for early detection of esophageal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia at the Digestive Disease Week (DDW) Annual Meeting 2024. The studies aim to expand the clinical evidence base for EsoGuard testing to detect esophageal precancer and introduce a new genetic classifier.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
News
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a business update conference call and webcast to discuss operational updates, growth strategy, and financial results for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) received notification from the World Trade Center Health Program regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. Lucid is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
Rhea-AI Summary
Lucid Diagnostics Inc. highlights EsoCheck's advanced cell collection technology during testimony before the U.S. House of Representatives' Committee on Small Business. EsoCheck's innovative Collect & Protect® technology offers precise, noninvasive esophageal cell collection, leading to unprecedented early precancer detection results. The device's efficiency allows for high-volume testing events, with excellent patient satisfaction and DNA yields. In contrast, older 'sponge-on-a-string' technologies lack EsoCheck's precision and protection features, resulting in poor sensitivity and mechanical failures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
News
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
Rhea-AI Summary
Lucid Diagnostics Inc. announces a contract with the World Trade Center Health Program to provide EsoGuard Esophageal DNA test as a covered benefit to more than 120,000 responders and survivors of the 9/11 terrorist attacks. The test is reimbursable at $2,475.81 per test prescribed by clinicians at WTCHP's Clinical Centers of Excellence. This initiative aims to expand patient access to EsoGuard testing and prevent esophageal cancer and cancer deaths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
News
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced the publication of three clinical utility studies demonstrating the real-world clinical utility of Lucid's EsoGuard Esophageal DNA test to detect esophageal precancer. The studies document near-perfect concordance between EsoGuard results and the prescribing physician's decision whether to refer patients for upper endoscopy, with 100 percent of EsoGuard-positive patients being referred for confirmatory upper endoscopy. These results eliminate the need for hundreds of costly, invasive, and inconvenient endoscopies, demonstrating that EsoGuard allows physicians to appropriately triage at-risk patients, consistent with established professional society guidelines, and ensure cost-effective utilization of endoscopy in esophageal precancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Stock LUCD logo
Lucid Diagnostics Inc

Nasdaq:LUCD

LUCD Rankings

#4846 Ranked by Market Cap
#3996 Ranked by Stock Gains
N/A Ranked by Dividends

LUCD Stock Data

39.03M
15.07M
70.39%
3.66%
0.91%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
New York